Physician profile
Sunil Dacha
NPI 1548424211
$4,901.69
in general payments reported to CMS, 2019-2025
31 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $132 · 2021: $350 · 2022: $568 · 2023: $547 · 2024: $807 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,324.63 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Boston Scientific Corporation | $841.26 | 2019-2024 | Orise, Apollo Esg Nxt System, Axios |
| Olympus Corporation of The Americas | $546.50 | 2019 | |
| Medtronic, INC. | $280.19 | 2022-2025 | Nexpowder, Dragonfly Pancreaticobiliary Scope and Instrument Channel Caps |
| Takeda Pharmaceuticals U.S.A., INC. | $256.22 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $248.09 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.27 | 2019-2025 | Xifaxan |
| Pentax of America, INC. | $137.72 | 2019 | |
| Cook Medical LLC | $126.99 | 2025 | Hemospray |
| Apollo Endosurgery US INC | $115.70 | 2021-2023 | Overstitch Endoscopic Suturing System |
| Erbe USA INC | $100.00 | 2025 | Vio3 |
| Aimmune Therapeutics, INC. | $80.93 | 2025 | Zenpep |
| Conmed Corporation | $80.87 | 2022 | |
| Ferring Pharmaceuticals INC. | $59.41 | 2022-2025 | Rebyota |
| Shire North American Group INC | $51.70 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.10 | 2024 | |
| Eisai INC. | $45.89 | 2019-2020 | |
| Ardelyx, INC. | $45.21 | 2025 | Ibsrela |
| Olympus America INC. | $45.14 | 2021 | |
| Celgene Corporation | $34.49 | 2022-2023 | Zeposia |
| Ambu INC. | $34.09 | 2024-2025 | |
| Enterra Medical, INC. | $33.49 | 2025 | |
| Braintree Laboratories, INC. | $32.88 | 2019-2024 | Suflave, Sutab |
| Lilly USA, LLC | $30.01 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $24.65 | 2025 | Rezdiffra |
| Romark Laboratories, Lc | $24.10 | 2019 | |
| Phathom Pharmaceuticals, INC. | $20.82 | 2024 | Voquezna |
| Celltrion USA INC. | $20.13 | 2024 | Vegzelma |
| Daiichi Sankyo INC. | $19.26 | 2019 | |
| Alfasigma USA, INC. | $16.74 | 2020 | |
| Allergan, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Dacha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.